Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetics and the treatment of chronic myeloid leukemia: how relevant clinically? An update.

Pharmacogenomics - 1 Apr 2018

Ankathil Ravindran, Azlan Husin, Dzarr Abu Abdullah, Baba Abdul Aziz

Abstract excerpt

Despite the excellent efficacy and improved clinical responses obtained with imatinib mesylate (IM), development of resistance in a significant proportion of chronic myeloid leukemia (CML) patients on IM therapy have emerged as a challenging problem in clinical practice. Resistance to imatinib can be due to heterogeneous array of factors involving BCR/ABL-dependent and BCR/ABL-independent pathways. Although...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BCR gene

Share to Imatinib Mesylate

Share to Leukemia, Myeloid, Acute

Share to Pharmacogenetics

Share to Polymorphism, Single Nucleotide

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 29569526
DOI: 10.2217/pgs-2017-0193

Genes

BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetics and the treatment of chronic myeloid leukemia: how relevant clinically? An update.PMID 29569526Read ↗

Do genetic polymorphisms influence imatinib trough concentrations in patients with chronic myeloid leukemia? A systematic review and meta-analysis.Semantic proximity Read ↗

Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid LeukemiaSemantic proximity Read ↗

Influence of MDR1 and CYP3A5 genetic polymorphisms on trough levels and therapeutic response of imatinib in newly diagnosed patients with chronic myeloid leukemia.Semantic proximity Read ↗

Pharmacogenomics in acute myeloid leukemia.Semantic proximity Read ↗

Association of the Trough, Peak/Trough Ratio of Imatinib, Pyridine–N-Oxide Imatinib and ABCG2 SNPs 34 G>A and SLCO1B3 334 T>G With Imatinib Response in Egyptian Chronic Myeloid Leukemia PatientsSemantic proximity Read ↗

Influence of CYP2C8*3 and ABCG2 C421A genetic polymorphisms on trough concentration and molecular response of imatinib in Egyptian patients with chronic myeloid leukemia.Semantic proximity Read ↗

ABCB1 haplotypes but not individual SNPs predict for optimal response/failure in Egyptian patients with chronic-phase chronic myeloid leukemia receiving imatinib mesylate.Semantic proximity Read ↗

A Study to Explore the Role of IDH1 (R132) Mutation on Imatinib Toxicity and Effect of ABCG2/OCT1 Expression on N-Desmethyl Imatinib Plasma Level in Egyptian Chronic Myeloid Leukemia Patients.Semantic proximity Read ↗

Clinical impact of ABCC1 and ABCC2 genotypes and haplotypes in mediating imatinib resistance among chronic myeloid leukaemia patients.Semantic proximity Read ↗

MDR1 gene polymorphisms and imatinib response in chronic myeloid leukemia: A meta-analysis.Semantic proximity Read ↗

Role of ADME gene polymorphisms on imatinib disposition: results from a population pharmacokinetic study in chronic myeloid leukaemia.Semantic proximity Read ↗

Influence of genetic polymorphisms on imatinib concentration and therapeutic response in patients with chronic-phase chronic myeloid leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.